2012-05-10T09:42:13-05:00 2011-06-30 CLARK NUBER PS 10900 NE 4TH STREET SUITE 1700 BELLEVUE WA 98004 990 2010-07-01 910961784 SEATTLE BIOMEDICAL RESEARCH INSTITUTE SEAT 2062567200 307 WESTLAKE AVENUE NORTH NO 500 SEATTLE WA 981095219 RANDAL HASSLER 2062567200 2012-04-15 1 JANE M SEARING 4254544919 2010 2016-02-24 21:20:13Z SEATTLE BIOMED RANDAL HASSLER 307 WESTLAKE AVENUE NORTH NO 500 SEATTLE WA 981095219 51593957 0 X WWW.SEATTLEBIOMED.ORG X 1976 WA TO ELIMINATE THE WORLD'S MOST DEVASTATING INFECTIOUS DISEASES. 20 20 366 47 228352 225652 46090916 48141286 239657 344293 276722 469503 2340654 2431578 48947949 51386660 0 0 0 0 17513847 19378878 0 0 722591 33076016 27231062 50589863 46609940 -1641914 4776720 37706828 42541497 17761031 17648536 19945797 24892961 X CONDUCT RESEARCH LEADING TO THE PREVENTION, DIAGNOSIS, AND CURE OF GLOBAL HEALTH INFECTIOUS DISEASES INCLUDING MALARIA, HIV/AIDS AND TB, WHICH ARE DISEASES RESPONSIBLE FOR THE DEATHS OF 14 MILLION EACH YEAR. 0 0 13645665 85929 EMERGING & NEGLECTED DISEASES: THE RESEARCH IN THIS PROGRAM FOCUSES ON THE DISCOVERY OF NEW DRUGS AND BIOMARKERS FOR EMERGING AND NEGLECTED DISEASES, SUCH AS THOSE CAUSED BY TRYPANOSOMATIDS. MAJOR SCIENTIFIC ADVANCES INCLUDE EVALUATING T. BRUCEI CANDIDATE DRUG TARGETS, IDENTIFYING INHIBITORS OF T. GONDII, SOLVING THE STRUCTURES OF OVER 450 PROTEINS OF EMERGING INFECTIONS PATHOGENS, AND DEVELOPING DIAGNOSTIC REAGENTS FOR TRYPANOSOMES AND OTHER PARASITES. SEATTLE BIOMED HAS FIVE PRINCIPAL INVESTIGATORS COMMITTED TO THIS RESEARCH. 12670380 79541 MALARIA: THE RESEARCH IN THIS PROGRAM FOCUSES ON DEVELOPING VACCINES AND DRUGS FOR EARLY STAGE MALARIA, SEVERE MALARIA IN CHILDREN, AND PREGNANCY MALARIA. SEATTLE BIOMED RESEARCHERS HAVE MADE FUNDAMENTAL DISCOVERIES IN IDENTIFYING MALARIA ANTIGENS THAT ARE CANDIDATES FOR TESTING AS VACCINES IN HUMANS, TESTING A GENETICALLY ATTENUATED PARASITE AS A VACCINE IN HUMANS, ELUCIDATING PARASITE PATHWAYS AS POTENTIAL DRUG TARGETS, AND CONDUCTING TWO TRIALS AT SEATTLE BIOMED'S MALARIA CLINICAL TRIALS CENTER. SEATTLE BIOMED HAS SIX PRINCIPAL INVESTIGATORS AND TWO TRIALS INVESTIGATORS COMMITTED TO THIS RESEARCH. 8322394 52246 VIRAL DISEASES: THE TARGET OF SEATTLE BIOMED'S VIRAL DISEASES PROGRAM IS TO DEVELOP VACCINES FOR HIV/AIDS AND OTHER HUMAN VIRUS, SUCH AS THE INFLUENZA VIRUS. MAJOR PROGRESS HAS BEEN MADE IN UNCOVERING FUNDAMENTAL MECHANISMS THAT GOVERN IMMUNE RESPONSES TO VIRAL INFECTIONS, ANALYZING DATA FROM CLINICAL SAMPLES COLLECTED DURING THE HIV VACCINE STEP TRIAL, DEFINING NEONATE IMMUNE RESPONSES TO VACCINES, DEFINING THE ROLE OF INFLAMMATION ON HIV TRANSMISSION, AND DEVELOPING IMMUNOGENS THAT ELICIT BROADLY ANTI-HIV NEUTRALIZING ANTIBODIES, AND INITIATING STUDIES TO INVESTIGATE CO-INFECTIONS OF HIV WITH OTHER PATHOGENS, SUCH AS TB. SEATTLE BIOMED HAS FOUR PRINCIPAL INVESTIGATORS COMMITTED TO THIS RESEARCH. 4364590 27135 TUBERCULOSIS: THE RESEARCH IN THIS PROGRAM FOCUSES ON THE DISCOVERY OF NEW DRUGS AND BIOMARKERS FOR TB, IN PART BY STUDYING THE INTERACTIONS BETWEEN THE HOST AND THE PATHOGEN. RECENT PROGRESS INCLUDES IDENTIFYING THE ROLE OF SPECIFIC TB PROTEINS IN BACTERIALS PERSISTENCE, DEVELOPING A STREAMLINED APPROACH TO IDENTIFY DRUG TARGETS, ESTABLISHING ASSAYS FOR NEW TB DRUGS, CHARACTERIZING THE HOST RESPONSE TO INFECTION AND VACCINATION, AND DEVELOPING A LOW-COST, POINT-OF-CARE DIAGNOSTIC TEST THAT CAN DETECT ACTIVE TB DISEASE. SEATTLE BIOMED HAS FOUR PRINCIPAL INVESTIGATORS COMMITTED TO THIS RESEARCH. 870472 99442 BIOQUEST: THE PRIMARY GOAL OF SEATTLE BIOMED SCIENCE OUTREACH PROGRAM, BIOQUEST, IS TO PROVIDE A CURRICULUM-RELEVANT, CAREER-INSPIRING, TECHNOLOGY-RICH SCIENCE EDUCATION PROGRAM WITHIN THE CONTEXT OF INFECTIOUS DISEASE RESEARCH TO HIGH SCHOOL STUDENTS, TEACHERS, AND THE GENERAL PUBLIC. WE ARE THE ONLY ORGANIZATION IN THE NATION TO OFFER A 32-PERSON TEACHING LAB, WITHIN THE FOOTPRINT OF AN INFECTIOUS DISEASE RESEARCH INSTITUTE. 5235062 126577 39873501 1 1 0 1 0 0 0 0 1 1 0 0 0 1 0 1 0 0 0 1 0 0 0 1 0 0 0 0 1 0 0 0 1 0 0 0 0 1 0 0 0 0 0 0 0 0 0 1 52 0 1 366 1 1 1 0 0 0 0 1 1 0 0 0 0 X 20 20 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 1 0 WA X X RANDAL HASSLER 2062567200 307 WESTLAKE AVE N 500 SEATTLE WA 981095219 TODD PATRICK 5.00 X X 0 0 0 TREVOR MOODY 5.00 X X 0 0 0 MIKE STULL 5.00 X X 0 0 0 DARRYL JOHNSON 5.00 X X 0 0 0 MAUD DAUDON 5.00 X 0 0 0 DEAN ALLEN 5.00 X 0 0 0 ROSEMARY BARKER ARAGON 5.00 X 0 0 0 JANE A BIDDLE PHD 5.00 X 0 0 0 GREGG BLODGETT 5.00 X 0 0 0 MARLYN FRIEDLANDER 5.00 X 0 0 0 JANE HEDREEN 5.00 X 0 0 0 ALAN LEVY PHD 5.00 X 0 0 0 NEIL MCDONNELL PHARMD 5.00 X 0 0 0 TERRENCE R MEERSMAN 5.00 X 0 0 0 CHRISTOPHER H PORTER PHD 5.00 X 0 0 0 ERICK RABINS 5.00 X 0 0 0 GREG SIMON JD 5.00 X 0 0 0 MOYA VAZQUEZ 5.00 X 0 0 0 MELISSA YEAGER 5.00 X 0 0 0 KRIS RICHEY 5.00 X 0 0 0 KENNETH STUART PHD 55.00 X 274613 0 33537 RANDAL HASSLER 50.00 X 181390 0 29287 MICHAEL PODLIN 40.00 X 170933 0 21223 MARILYN PARSONS PHD 47.00 X 151696 0 21970 IAN NICHOLAS CRISPE MD PHD 50.00 X 208360 0 27226 THEODORE WHITE PHD 40.00 X 157999 0 13982 LEONIDAS STATMATATOS PHD 50.00 X 143306 0 23879 KAREN BLOCHLINGER PHD JD 50.00 X 146099 0 18658 ANGELA TALLY MD 50.00 X 133522 0 16415 1567918 0 206177 21 0 1 0 EMERALD BIOSTRUCTURES 7869 NE DAY ROAD WEST BAINBRIDGE ISLAND WA 98110 RESEARCH 3150388 UNIVERSITY OF WASHINGTON BOX 352100 SEATTLE WA 981952100 RESEARCH 2454463 FRED HUTCHINSON CANCER RESEARCH CENTER 1100 FAIRVIEW AVENUE NORTH SEATTLE WA 98109 PROTEIN ANALYSIS 654856 MOROGORO HOSPITAL RWEGASORE ROAD MOROGORO TZ RESEARCH 550544 INFECTIOUS DISEASE RESEARCH INSTITUTE 1124 COLUMBIA STREET SUITE 400 SEATTLE WA 98104 DRUG SCREENING 376000 20 301270 27858893 19981123 80000 48141286 RESEARCH SUPPORT SRVCS 541900 217026 217026 EDUCATION PROGRAM 611600 99442 99442 PROGRAM SERVICE FEES 541900 27825 27825 344293 489016 489016 2566162 60531 2505631 2505631 228352 2277279 8500 28013 -19513 -19513 -19513 44700 301270 118753 -74053 -74053 51386660 344293 228352 2672729 847387 488810 227517 131060 14739631 13116637 1400147 222847 1108888 953495 124919 30474 1254789 1086980 136986 30823 1428183 1240127 154314 33742 100097 88182 11915 74956 74956 121406 58216 57821 5369 1453759 995264 415054 43441 7675 6554 1001 120 1220263 1042033 159134 19096 492713 420748 64255 7710 4630894 2209015 2388960 32919 406099 385198 18476 2425 335405 204207 39905 91293 192505 146057 44124 2324 1780244 1451398 312396 16450 276223 124538 150623 1062 SUBCONTRACTS 11236346 11236346 RESEARCH SUPPLIES 3714325 3594569 107302 12454 EQUIPMENT RENTAL & MAIN 602622 537863 59193 5566 585530 487264 64850 33416 46609940 39873501 6013848 722591 6395094 1900 12642802 21201147 6256508 9868536 74404 139164 174627 86148 98482 202684 49042 24758 306940 335908 23695226 13524443 10934896 10170783 405825 335712 368208 174757 37706828 42541497 4593542 4704534 8375988 9137254 3481384 2608351 1310117 1198397 17761031 17648536 X 13295192 14367007 6600605 10525954 50000 0 19945797 24892961 37706828 42541497 X 4776720 170444 X 0 1 1 X 1 1 X UNIVERSITY OF WASHINGTON MEDICAL CENTER SEATTLE WA WALTER REED ARMY INSTITUTE OF RESEARCH SILVER SPRING MD MOROGORO REGIONAL HOSPITAL MOROGORO TZ SCHEDULE A, PART IV, SUPPLEMENTAL INFORMATION: THESE HOSPITAL AFFILIATIONS ALLOW SEATTLE BIOMED TO QUALIFY AS A MEDICAL RESEARCH ORGANIZATION. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 1 0 0 0 0 1 121406 0 0 121406 0 EXPLANATION OF OTHER LOBBYING ACTIVITIES: PART II-B, LINE 1I: SEATTLE BIOMED HIRED AN INDEPENDENT LOBBYIST TO LOBBY THE LEGISLATURE ON ISSUES INVOLVING THE ORGANIZATION'S MISSION. 50000 -50000 50000 50000 50000 50000 0.00000 0.00000 0.00000 0 0 20503 20503 0 11261461 4457395 6804066 11579098 8304188 3274910 834164 742357 91807 10170783 FAIR VALUE OF INTEREST RATE SWAP 95564 DEFERRED RENT LIABILITY 1102833 1198397 51386660 46609940 4776720 170444 170444 4947164 51574126 9296 95128 104424 51469702 -83042 -83042 51386660 46626962 9296 7726 17022 46609940 0 46609940 DESCRIPTION OF INTENDED USE OF ENDOWMENT FUNDS: PART V, LINE 4: WE CONTINUE TO REINVEST FOR UNRESTRICTED EARNINGS. THE REMAINDER OF THE ENDOWMENT FUNDS WERE RELEASED FROM RESTRICTION DURING THE TAX YEAR ENDED JUNE 30, 2011. PART XI, LINE 8 - OTHER ADJUSTMENTS: CHANGE IN FAIR VALUE OF INTEREST RATE SWAP AGREEMENT 95,128. RENTAL EXPENSE FROM 307 WESTLAKE, LLC 60,531. BOOK/TAX DIFFERENCE FROM INVESTMENT IN 307 WESTLAKE, LLC 14,785. PART XII, LINE 2D - OTHER ADJUSTMENTS: CHANGE IN FAIR MARKET VALUE OF INTEREST RATE SWAP 95,128. PART XII, LINE 4B - OTHER ADJUSTMENTS: BOOK/TAX DIFFERENCE FROM INVESTMENT IN 307 WESTLAKE -14,785. LOSS ON DISPOSAL OF FIXED ASSETS -4,577. RENTAL EXPENSE -60,531. SPECIAL EVENT DEDUCTIONS -3,149. PART XIII, LINE 2D - OTHER ADJUSTMENTS: LOSS ON SALE OF FIXED ASSETS 4,577. SPECIAL EVENT DEDUCTIONS 3,149. EAST ASIA AND THE PACIFIC 0 4 PROGRAM SERVICES EMERGING INFECTIONS AND MALARIA 146222 EUROPE 0 11 PROGRAM SERVICES MALERIA, HIV AND TB 873699 SOUTH ASIA 0 1 PROGRAM SERVICES EMERGING INFECTIONS 15000 SUB-SAHARAN AFRICA 0 3 PROGRAM SERVICES MALARIA AND TB 655541 NORTH AMERICA 0 3 PROGRAM SERVICES MALARIA AND HIV 54804 NORTH AMERICA 0 0 ADMINISTRATIVE COSTS 24509 EAST ASIA AND THE PACIFIC 0 0 ADMINISTRATIVE COSTS 8743 0 22 0 0 0 22 1778518 0 1778518 0 0 0 0 0 0 METHOD USED TO ACCCOUNT FOR EXPENDITURES: SCHEDULE F, PART I, LINE 3: THE ACCRUAL METHOD OF ACCOUNTING IS USED TO ACCOUNT FOR EXPENDITURES. PASSPORT DINNER 345970 301270 44700 3150 76900 38703 345970 301270 44700 3150 76900 38703 118753 -74053 X X X X 0 0 0 0 0 0 0 0 0 KENNETH STUART PHD 270663 0 3950 0 0 0 29414 0 4123 0 308150 0 0 0 RANDAL HASSLER 181390 0 0 0 0 0 19792 0 9495 0 210677 0 0 0 MICHAEL PODLIN 170933 0 0 0 0 0 18000 0 3223 0 192156 0 0 0 MARILYN PARSONS PHD 151696 0 0 0 0 0 16062 0 5908 0 173666 0 0 0 IAN NICHOLAS CRISPE MD PHD 208360 0 0 0 0 0 20569 0 6657 0 235586 0 0 0 THEODORE WHITE PHD 157999 0 0 0 0 0 11739 0 2243 0 171981 0 0 0 LEONIDAS STATMATATOS PHD 143306 0 0 0 0 0 15229 0 8650 0 167185 0 0 0 KAREN BLOCHLINGER PHD JD 146099 0 0 0 0 0 18658 0 0 0 164757 0 0 0 NICK CRISPE X 80000 86148 0 1 1 86148 X EQUIPMENT 1 80000 FAIR MARKET VALUE 0 0 1 0 METHOD FOR DETERMINING NUMBER OF CONTRIBUTORS: PART I, COLUMN (B): THIS COLUMN REPRESENTS THE NUMBER OF CONTRIBUTORS. FORM 990, PART I, LINE 6 VOLUNTEER ACTIVITY, INCLUDING NUMBER OF VOLUNTEERS AND HOURS CONTRIBUTED, ARE TRACKED AT EACH EVENT. INCLUDING BOARD MEMBERS TIME, TOTAL VOLUNTEER HOURS WERE 1,400. BOARD ENGAGEMENT REPRESENTS 75% OF VOLUNTEER HOURS AND THE REMAINING 25% IS FROM COMMUNITY MEMBERS ACTIVE WITH THE EDUCATION PIECE OF OUR MISSION. FORM 990, PART VI, SECTION B, LINE 11 THE RETURN WILL BE REVIEWED IN DETAIL BY THE CHIEF OPERATING OFFICER. IN ADDITION, OUR TAX PREPARER WILL PRESENT THE 990 TO THE FINANCE AND AUDIT COMMITTEE. A FINAL DRAFT WILL BE ELECTRONICALLY SENT TO ALL TRUSTEES OF SEATTLE BIOMED. OUR BOARD LIAISON WILL MONITOR THE DISTRIBUTION OF THE RETURN AND WILL COLLECT COMMENTS AND RESPONSES AND REPORT THESE TO THE CONTROLLER PROMPTLY. ANY PERTINENT RESPONSES WILL BE ADDRESSED AND RESOLVED BEFORE THE FINAL TAX RETURN IS FILED. FORM 990, PART VI, SECTION B, LINE 12C EACH TRUSTEE (AND ALL KEY EMPLOYEES) AND MEMBER OF A COMMITTEE WITH BOARD DELEGATED POWERS SHALL ANNUALLY SIGN A STATEMENT WHICH AFFIRMS THAT SUCH PERSON HAS RECEIVED A COPY OF THE CONFLICT OF INTEREST POLICY, HAS READ AND UNDERSTANDS THE POLICY, AND AGREES TO COMPLY WITH THE POLICY. IF ANY KNOWN CONFLICTS ARISE, THEY ARE SENT TO THE EXECUTIVE COMMITTEE FOR RESOLUTION. A FOLLOWUP TO THE LEADERSHIP TEAM THEN OCCURS, IF NEEDED. PROCEDURES: 1. DUTY TO DISCLOSE: IN CONNECTION WITH ANY ACTUAL OR POSSIBLE CONFLICT OF INTEREST, AN INTERESTED PERSON MUST DISCLOSE THE EXISTENCE AND NATURE OF HIS/HER FINANCIAL INTEREST TO THE EXECUTIVE COMMITTEE OF THE BOARD OF TRUSTEES PRIOR TO CONSIDERATION OF THE PROPOSED TRANSACTION OR ARRANGEMENT AND MUST NOT ENTER INTO ANY ARRANGEMENT WHERE THERE IS AN ACTUAL OR POTENTIAL CONFLICT OF INTEREST WITHOUT EXECUTIVE COMMITTEE APPROVAL. 2. DETERMINING WHETHER A CONFLICT OF INTEREST EXISTS: AFTER DISCLOSURE OF THE FINANCIAL INTEREST, THE INTERESTED PERSON SHALL RECUSE HIMSELF/HERSELF WHILE THE FINANCIAL INTEREST IS DISCUSSED AND VOTED UPON. THE EXECUTIVE COMMITTEE SHALL DECIDE IF A CONFLICT OF INTEREST EXISTS. 3. PROCEDURES FOR ADDRESSING THE CONFLICT OF INTEREST: A. THE EXECUTIVE COMMITTEE SHALL, IF APPROPRIATE, APPOINT A DISINTERESTED PERSON OR COMMITTEE TO INVESTIGATE ALTERNATIVES TO THE PROPOSED TRANSACTION OR ARRANGEMENT. B. AFTER EXERCISING DUE DILIGENCE, THE BOARD OR COMMITTEE SHALL DETERMINE WHETHER SEATTLE BIOMED CAN OBTAIN A MORE ADVANTAGEOUS TRANSACTION OR ARRANGEMENT WITH REASONABLE EFFORTS FROM A PERSON OR ENTITY THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST. C. IF A MORE ADVANTAGEOUS TRANSACTION OR ARRANGEMENT IS NOT REASONABLY ATTAINABLE UNDER CIRCUMSTANCES THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST, THE BOARD OR COMMITTEE SHALL DETERMINE BY A MAJORITY VOTE OF THE DISINTERESTED MEMBERS WHETHER THE TRANSACTION OR ARRANGEMENT IS IN SEATTLE BIOMED'S BEST INTEREST AND FOR ITS OWN BENEFIT AND WHETHER THE TRANSACTION IS FAIR AND REASONABLE TO SEATTLE BIOMED AND SHALL MAKE ITS DECISION AS TO WHETHER TO ENTER INTO THE TRANSACTION OR ARRANGEMENT IN CONFORMITY WITH SUCH DETERMINATION. 4. VIOLATIONS OF THE CONFLICTS OF INTEREST POLICY: A.IF THE BOARD, A COMMITTEE, SEATTLE BIOMED STAFF OR A TRUSTEE HAS REASONABLE CAUSE TO BELIEVE THAT A TRUSTEE OR A COMMITTEE MEMBER HAS FAILED TO DISCLOSE AN ACTUAL OR POSSIBLE CONFLICT OF INTEREST, IT SHALL INFORM THE MEMBER OF THE BASIS FOR SUCH BELIEF AND AFFORD THE MEMBER THE OPPORTUNITY TO EXPLAIN THE ALLEGED FAILURE TO DISCLOSE. B. IF, AFTER HEARING THE RESPONSE OF THE MEMBER AND MAKING SUCH FURTHER INVESTIGATION AS MAY BE WARRANTED IN THE CIRCUMSTANCES, THE EXECUTIVE BOARD DETERMINES THAT THE MEMBER HAS, IN FACT, FAILED TO DISCLOSE AN ACTUAL OR POSSIBLE CONFLICT OF INTEREST, IT SHALL TAKE APPROPRIATE DISCIPLINARY AND CORRECTIVE ACTION. FORM 990, PART VI, SECTION B, LINE 15 COMPENSATION PLANNING AND REVIEW TAKES PLACE ANNUALLY. HUMAN RESOURCES PROVIDES MARKET DATA FOR EACH POSITION IN THE INSTITUTE. FOR SENIOR LEADERSHIP POSITIONS, SPECIFICALLY KEY EMPLOYEES, AN OUTSIDE COMPENSATION CONSULTANT BENCHMARKS THESE POSITIONS AND PROVIDES DATA AND ANALYSIS, WHICH ALLOWS US TO ESTABLISH A PAY RANGE FOR EACH OF THESE ROLES AT OUR INSTITUTE. WE ALSO GATHER INDUSTRY-SPECIFIC INFORMATION FROM OUR PEERS TO VALIDATE THE SURVEY INFORMATION AND TO ENSURE THAT WE REMAIN COMPETITIVE WITH OUR COMPENSATION. THIS INFORMATION IS GATHERED FROM LOCAL PEER ORGANIZATIONS IN OUR INDUSTRY AND/OR FROM PEER ORGANIZATIONS WHO ARE PART OF THE ASSOCIATION OF INDEPENDENT RESEARCH INSTITUTES (AIRI). THE MOST RECENT COMPENSATION REVIEW TOOK PLACE IN JANUARY 2012. FORM 990, PART VI, SECTION C, LINE 19 THE GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE AVAILABLE UPON REQUEST. THE FINANCIAL STATEMENTS ARE ALSO AVAILABLE ON SEATTLE BIOMED'S WEBSITE. FORM 990, PART VI, LINE 16B THE ORGANIZATION IS IN THE PROCESS OF DEVELOPING A JOINT VENTURE POLICY. CHANGES IN NET ASSETS OR FUND BALANCES: FORM 990, PART XI, LINE 5: CHANGE IN FAIR VALUE OF INTEREST RATE SWAP AGREEMENT 95,128. RENTAL EXPENSE FROM 307 WESTLAKE, LLC 60,531. BOOK/TAX DIFFERENCE ON INVESTMENT IN 307 WESTLAKE 14,785. TOTAL TO FORM 990, PART XI, LINE 5: 170,444.